![Bogdan Dziurzynski](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bogdan Dziurzynski
No más puestos en curso
Historial de carrera de Bogdan Dziurzynski
Antiguos cargos conocidos de Bogdan Dziurzynski.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
DENDREON CORPORATION | Director/Miembro de la Junta | 01/05/2001 | 23/02/2015 |
Independent Dir/Board Member | 01/05/2001 | 23/02/2015 | |
ANTHERA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 05/03/2012 | 10/06/2014 |
Independent Dir/Board Member | 05/03/2012 | 10/06/2014 | |
MedImmune LLC
![]() MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Consejero General | 01/01/1994 | 01/01/2001 |
Immunex Corp.
![]() Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Consejero General | 01/01/1988 | 01/01/1994 |
JOHNSON & JOHNSON | Corporate Officer/Principal | - | - |
C.R. BARD | Corporate Officer/Principal | - | - |
Genetic Systems Corp. | Corporate Officer/Principal | 20/04/2010 | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Director/Miembro de la Junta | 01/01/2009 | - |
Regulatory Affairs Professionals Society
![]() Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Regulatory Affairs Professionals Society is a non-profit organization that offers healthcare products. The non-profit company is based in Rockville, MD. | Presidente | - | - |
░░░░░░░░░ ░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formación de Bogdan Dziurzynski.
Rutgers State University of New Jersey | Undergraduate Degree |
Seattle University | Masters Business Admin |
University of Southern California | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 13 |
Canadá | 2 |
Operativa
Director/Board Member | 4 |
Corporate Officer/Principal | 3 |
Independent Dir/Board Member | 2 |
Sectorial
Health Technology | 7 |
Consumer Services | 4 |
Commercial Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
JOHNSON & JOHNSON | Health Technology |
ANTHERA PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 8 |
---|---|
Dendreon Corp.
![]() Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
Biologics Consulting Group, Inc.
![]() Biologics Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Biologics Consulting Group, Inc. provides regulatory and product development advisory services for drugs and device products. It specializes in the preparation and review of CBER, CDER and CDRH regulatory applications, facility inspection, process validation packages, and electronic submissions. The company was founded by James G. Kenimer in 1993 and is headquartered in Alexandria, VA. | Commercial Services |
Regulatory Affairs Professionals Society
![]() Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Regulatory Affairs Professionals Society is a non-profit organization that offers healthcare products. The non-profit company is based in Rockville, MD. | Commercial Services |
MedImmune LLC
![]() MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Immunex Corp.
![]() Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
Genetic Systems Corp. | |
C. R. Bard, Inc. (New Jersey)
![]() C. R. Bard, Inc. (New Jersey) Medical SpecialtiesHealth Technology C. R. Bard, Inc. engages in designing, development, manufacturing, packaging, distribution, and sales of medical, surgical, diagnostic, and patient care devices. It sells its products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. The company was founded by Charles Russell Bard in 1907 and is headquartered in Franklin Lakes, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Bogdan Dziurzynski
- Experiencia